Celcuity Inc. to Announce Third Quarter 2024 Financial Results
MINNEAPOLIS — Celcuity Inc. (Nasdaq: CELC), a pioneering biotechnology company focused on advancing targeted therapies for oncology, has scheduled the release of its financial outcomes for the third quarter of 2024. This critical announcement will occur after the market concludes trading on a Thursday.
Details About the Webcast and Conference Call
Management at Celcuity will hold a webcast and teleconference on the same day at 4:30 p.m. Eastern Time to outline the results and provide additional insights regarding the company’s progress.
How to Join the Teleconference
Domestic callers interested in participating should use the number 1-800-717-1738, while international participants can reach the conference at 1-646-307-1865. The live webcast will be accessible through the Celcuity website, where attendees can engage in the presentation and later access a replay of the event.
About Celcuity and Its Innovative Therapies
Celcuity is dedicated to the development of cutting-edge therapies targeting various solid tumor conditions. The flagship therapeutic candidate is gedatolisib, known for being a potent pan-PI3K and mTOR inhibitor. It’s essential to highlight that gedatolisib exhibits a unique mechanism of action, distinguishing it from the currently available companies targeting similar pathways.
Clinical Trials Involving Gedatolisib
The company is currently conducting a Phase 3 clinical trial known as VIKTORIA-1, which assesses the effectiveness of gedatolisib combined with fulvestrant, and optionally palbociclib, in patients diagnosed with HR+/HER2- advanced breast cancer. Patient enrollment for this trial is ongoing.
Moreover, Celcuity has embarked on another Phase 1b/2 clinical trial titled CELC-G-201, aimed at evaluating gedatolisib alongside darolutamide for patients facing metastatic castration-resistant prostate cancer. The company also plans to initiate the VIKTORIA-2 trial, which will study gedatolisib in conjunction with a CDK4/6 inhibitor and fulvestrant, expected to start enrolling patients in the near future.
Corporate Contact Information for Celcuity Inc.
Celcuity's headquarters are located in the heart of Minneapolis, where they actively engage in the development of new oncology therapies. For more information or inquiries, you can reach out to:
Contacts:
Brian Sullivan
bsullivan@celcuity.com
Vicky Hahne
vhahne@celcuity.com
(763) 392-0123
For additional details, visit Celcuity's official site.
Frequently Asked Questions
What is the purpose of Celcuity's upcoming conference call?
The conference call is intended to discuss the financial results for the third quarter of 2024 and provide a corporate update.
How can I access the webcast of the conference call?
Participants can access the live webcast through the Celcuity website, where they can also find a replay of the event afterwards.
What is gedatolisib and why is it significant?
Gedatolisib is Celcuity's lead therapeutic candidate, recognized as a potent inhibitor of both pan-PI3K and mTOR, offering a unique approach in treating multiple solid tumor indications.
In which clinical trials is gedatolisib currently involved?
Gedatolisib is involved in several clinical trials, including the Phase 3 VIKTORIA-1 and the Phase 1b/2 CELC-G-201 trials, targeting advanced breast cancer and prostate cancer respectively.
Where can I find more information about Celcuity?
Additional information about Celcuity and its advancements in oncology can be found on their official website.